TNYA Tenaya Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Tenaya Therapeutics Inc reported revenue of $1.11M, net income of −$43.4M and diluted EPS of −$0.20; for the fiscal year ended December 2025 revenue was n/a.
TNYA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$93.3M, net income −$90.6M (margin n/a), EPS −$0.59
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$116M, net income −$111M (margin n/a), EPS −$1.31
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$131M, net income −$124M (margin n/a), EPS −$1.68
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$126M, net income −$124M (margin n/a), EPS −$2.76
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$72.8M, net income −$72.7M (margin n/a), EPS −$4.10
TNYA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.11M, net income −$43.4M, EPS −$0.20
- Quarter ended Mar 31, 2026: revenue $225K, net income −$19.3M, EPS −$0.09
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$20.2M, EPS −$0.09
- Quarter ended Sep 30, 2025: revenue n/a, net income −$20.3M, EPS −$0.12
- Quarter ended Jun 30, 2025: revenue $0, net income −$23.3M, EPS −$0.14
- Quarter ended Mar 31, 2025: revenue $0, net income −$26.9M, EPS −$0.24
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$23.8M, EPS −$0.27
- Quarter ended Sep 30, 2024: revenue n/a, net income −$25.6M, EPS −$0.30
- Quarter ended Jun 30, 2024: revenue n/a, net income −$29.4M, EPS −$0.34
- Quarter ended Mar 31, 2024: revenue n/a, net income −$32.2M, EPS −$0.40
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$29.9M, EPS −$0.41
- Quarter ended Sep 30, 2023: revenue n/a, net income −$29.1M, EPS −$0.39
- Quarter ended Jun 30, 2023: revenue n/a, net income −$33.3M, EPS −$0.45
- Quarter ended Mar 31, 2023: revenue n/a, net income −$31.7M, EPS −$0.43
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$33.5M, EPS −$0.58
- Quarter ended Sep 30, 2022: revenue n/a, net income −$30.7M, EPS −$0.74
- Quarter ended Jun 30, 2022: revenue n/a, net income −$28.4M, EPS −$0.69
- Quarter ended Mar 31, 2022: revenue n/a, net income −$31.1M, EPS −$0.75
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$26.2M, EPS $21.77
- Quarter ended Sep 30, 2021: revenue n/a, net income −$18.3M, EPS −$0.68
TNYA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$68.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$90.5M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$102M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$104M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$60.8M, share buybacks $13.0K
TNYA balance sheet
- Jun 30, 2026: cash $78.1M, total assets $93.5M, total liabilities $24.1M, shareholders' equity $69.4M
- Mar 31, 2026: cash $80.9M, total assets $135M, total liabilities $28.9M, shareholders' equity $106M
- Dec 31, 2025: cash $101M, total assets $147M, total liabilities $23.7M, shareholders' equity $123M
- Sep 30, 2025: cash $56.3M, total assets $105M, total liabilities $22.1M, shareholders' equity $82.9M
- Jun 30, 2025: cash $62.7M, total assets $122M, total liabilities $22.3M, shareholders' equity $99.8M
- Mar 31, 2025: cash $53.8M, total assets $144M, total liabilities $24.6M, shareholders' equity $119M
- Dec 31, 2024: cash $4.32M, total assets $120M, total liabilities $27.1M, shareholders' equity $92.9M
- Sep 30, 2024: cash $8.23M, total assets $141M, total liabilities $28.0M, shareholders' equity $113M
Is TNYA profitable?
No. Tenaya Therapeutics Inc lost $103M over the last four quarters.
What is TNYA's EPS?
Diluted earnings per share over the last four quarters were −$0.50; −$0.20 in the latest quarter.